Examining Non-Alcoholic Fatty Liver Disease in Patients with Inflammatory Bowel Disease
Prevalence of Non-Alcoholic Fatty Liver Disease in Inflammatory Bowel Disease Patients: A Prospective Monocentric Study
Centre Hospitalier Universitaire Saint Pierre · NCT06814600
This study looks at how common Non-Alcoholic Fatty Liver Disease is in people with Inflammatory Bowel Disease to see how gut health might affect liver health.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire Saint Pierre (other) |
| Locations | 1 site (Brussels) |
| Trial ID | NCT06814600 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) among patients diagnosed with Inflammatory Bowel Disease (IBD). It aims to understand the relationship between gut health and liver conditions, particularly focusing on the gut-liver axis. Participants will undergo transient elastometry to assess liver stiffness and steatosis levels. The study seeks to gather data that could illuminate the connection between IBD and liver health.
Who should consider this trial
Good fit: Ideal candidates are individuals diagnosed with Inflammatory Bowel Disease who are willing to provide informed consent.
Not a fit: Patients with established liver diseases or those with a history of excessive alcohol consumption will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of liver complications in IBD patients, leading to better management and treatment strategies.
How similar studies have performed: While the relationship between gut health and liver disease is being explored, this specific focus on NAFLD in IBD patients is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of IBD based on clinical, endoscopic, and histological gounds according to the latest ECCO guidelines * Willingness to provide informed consent for study participation Exclusion Criteria: * Presence of established liver disease (including autoimmune hepatitis, primary biliary cholangitis, primary biliary cirrhosis, hemochromatosis, Wilson's disease, positive serology for viral hepatitis B or C) * History of hepatocellular carcinoma or liver transplantation * History of excessive alcohol consumption defined as \>3 units per day for women and \> 5 units per day for men * Pregnancy at the time of recruitment * Failure to perform an elastography mesure or missing elastography data
Where this trial is running
Brussels
- CHU Saint Pierre — Brussels, Belgium (RECRUITING)
Study contacts
- Study coordinator: Jennifer Aoun, Medical Doctor
- Email: jennifer.aoun@stpierre-bru.be
- Phone: +3225353296
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: NAFLD, Inflammatory Bowel Diseases, Steatosis, Fibrosis, Liver